Article
Diminished functional role and altered localization of SHP2 in non-small cell lung cancer cells with EGFR-activating mutations.
Oncogene - 2 May 2013
Furcht C M, Muñoz Rojas A R, Nihalani D, Lazzara M J
Abstract excerpt
Non-small cell lung cancer (NSCLC) cells harboring activating mutations of the epidermal growth factor receptor (EGFR) tend to display elevated activity of several survival signaling pathways. Surprisingly, these mutations also correlate with reduced phosphorylation of ERK and SHP2, a protein tyrosine phosphatase required for complete ERK activation downstream of most receptor tyrosine kinases. As ERK activity...
Topics
- Adaptor Proteins, Signal Transducing
- Antineoplastic Agents
- Carcinoma, Non-Small-Cell Lung
- Cell Membrane
- ErbB Receptors
- Extracellular Signal-Regulated MAP Kinases
- Gefitinib
- Gene Knockdown Techniques
- Humans
- Lung Neoplasms
